These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30359208)

  • 1. Factors Affecting Relapse and Remission in Behçet's Uveitis Treated with Interferon Alpha2a.
    Celiker H; Kazokoglu H; Direskeneli H
    J Ocul Pharmacol Ther; 2019; 35(1):58-65. PubMed ID: 30359208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients.
    Lee JH; Lee CS; Lee SC
    BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis.
    Hasanreisoglu M; Cubuk MO; Ozdek S; Gurelik G; Aktas Z; Hasanreisoglu B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):71-75. PubMed ID: 26910383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
    Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
    Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-α2a induces CD4
    Zhu Y; Yu Q; Su G; Shao N; Feng J; Luo X; Zhou C; Yang P
    Clin Immunol; 2023 May; 250():109303. PubMed ID: 36997038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features.
    De Simone L; Invernizzi A; Aldigeri R; Mastrofilippo V; Marvisi C; Gozzi F; Bolletta E; Adani C; Pipitone N; Muratore F; Fontana L; Salvarani C; Cimino L
    Ocul Immunol Inflamm; 2022 Feb; 30(2):506-514. PubMed ID: 33021421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy.
    Yang P; Huang G; Du L; Ye Z; Hu K; Wang C; Qi J; Liang L; Wu L; Cao Q; Kijlstra A
    Ocul Immunol Inflamm; 2019; 27(1):7-14. PubMed ID: 29040035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features of patients with Behcet's uveitis].
    Liu XS; Gao F; Zhao C; Zhang MF
    Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
    Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
    Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet's uveitis.
    Shi J; Zhao C; Zhou J; Liu J; Wang L; Gao F; Zeng X; Zhang M; Zheng W
    Ther Adv Chronic Dis; 2019; 10():2040622319847881. PubMed ID: 31105923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study.
    Zaghetto JM; Yamamoto MM; Souza MB; Silva FT; Hirata CE; Olivalves E; Yamamoto JH
    Arq Bras Oftalmol; 2010; 73(1):40-6. PubMed ID: 20464112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.